{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:08:58Z","timestamp":1770512938907,"version":"3.49.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1097\/cco.0000000000000071","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T11:55:26Z","timestamp":1394711726000},"page":"274-283","source":"Crossref","is-referenced-by-count":41,"title":["Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer"],"prefix":"10.1097","volume":"26","author":[{"given":"Candice","family":"Yong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberechukwu","family":"Onukwugha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Daniel","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210128","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1589 patients.","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"R2-7-20210128","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity.","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R3-7-20210128","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease.","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"R4-7-20210128","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients quality of life, mobility, and functional independence.","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"issue":"Suppl 2","key":"R5-7-20210128","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.ejon.2007.07.002","article-title":"Burden of bone disease.","volume":"11","author":"Kinnane","year":"2007","journal-title":"Eur J Oncol Nurs"},{"key":"R6-7-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/CIA.S27930","article-title":"Management of bone metastases in refractory prostate cancer: role of denosumab.","volume":"7","author":"Paller","year":"2012","journal-title":"Clin Interv Aging"},{"key":"R7-7-20210128","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007).","volume":"184","author":"Norgaard","year":"2010","journal-title":"J Urol"},{"key":"R8-7-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries.","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R9-7-20210128","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/cncr.25762","article-title":"Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.","volume":"117","author":"Smith","year":"2011","journal-title":"Cancer"},{"key":"R10-7-20210128","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.urology.2012.04.007","article-title":"Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices.","volume":"80","author":"Freedland","year":"2012","journal-title":"Urology"},{"key":"R11-7-20210128","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R12-7-20210128","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"R13-7-20210128","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"R14-7-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/pcan.2012.42","article-title":"Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.","volume":"16","author":"Hagiwara","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R15-7-20210128","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1748-717X-7-168","article-title":"Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer.","volume":"7","author":"Hess","year":"2012","journal-title":"Radiat Oncol"},{"key":"R16-7-20210128","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","article-title":"Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer.","volume":"15","author":"DePuy","year":"2007","journal-title":"Support Care Cancer"},{"key":"R17-7-20210128","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R18-7-20210128","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"R19-7-20210128","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial).","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R20-7-20210128","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.clon.2013.03.003","article-title":"Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents.","volume":"25","author":"Poon","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R21-7-20210128","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1345\/aph.1P152","article-title":"Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.","volume":"44","author":"Spence","year":"2010","journal-title":"Ann Pharmacother"},{"key":"R22-7-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/pcan.2010.49","article-title":"The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.","volume":"14","author":"Velde","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R23-7-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3111\/13696998.2011.649324","article-title":"Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.","volume":"15","author":"Henk","year":"2012","journal-title":"J Med Econ"},{"key":"R24-7-20210128","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer.","volume":"14","author":"Lage","year":"2008","journal-title":"Am J Manag Care"},{"key":"R25-7-20210128","doi-asserted-by":"crossref","first-page":"693","DOI":"10.18553\/jmcp.2010.16.9.693","article-title":"Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.","volume":"16","author":"Barlev","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"R26-7-20210128","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2011.35.8648","article-title":"End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol"},{"key":"R27-7-20210128","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00520-013-1755-1","article-title":"Reducing the burden of bone metastases: current concepts and treatment options.","volume":"21","author":"von Moos","year":"2013","journal-title":"Support Care Cancer"},{"key":"R28-7-20210128","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.pcan.4500880","article-title":"The changing pattern of management for hormone-refractory, metastatic prostate cancer.","volume":"9","author":"James","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R29-7-20210128","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"R30-7-20210128","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1089\/jpm.2010.0491","article-title":"Self-reported rates of sleep disturbance in patients with symptomatic bone metastases attending an outpatient radiotherapy clinic.","volume":"14","author":"Khan","year":"2011","journal-title":"J Palliat Med"},{"key":"R31-7-20210128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jval.2010.11.014","article-title":"Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System.","volume":"14","author":"Felix","year":"2011","journal-title":"Value Health"},{"key":"R32-7-20210128","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3111\/13696998.2013.774279","article-title":"The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.","volume":"16","author":"Body","year":"2013","journal-title":"J Med Econ"},{"key":"R33-7-20210128","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3111\/13696998.2012.675380","article-title":"Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.","volume":"15","author":"Stopeck","year":"2012","journal-title":"J Med Econ"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:55:49Z","timestamp":1620950149000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201405000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000071","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}